A Phase II study to determine feasibility and safety of single agent MK-3475 in relapsed or refractory Peripheral T-cell Non-Hodgkin lymphoma
The goal of this clinical research study is to learn if pembrolizumab can help to control relapsed or refractory Peripheral T-cell non-Hodgkin lymphoma. The safety of this drug will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 10/12/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: